[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-atrophic-gastritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-atrophic-gastritis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100617493","objective-vascular-biomarkers-as-triage-for-depression-in-chronic-atrophic-gastritis-100617493",false,"NCT07319338","Objective Vascular Biomarkers as Triage for Depression in Chronic Atrophic Gastritis","Implementing Objective Vascular Biomarkers as a Non-stigmatizing Triage Workflow for Depression in Gastroenterology Settings: a Multicenter Study Protocol for a Hybrid Effectiveness-implementation Study","Inclusion Criteria:\n\n1. Age between 20 and 60 years, regardless of sex.\n2. Diagnosed with chronic atrophic gastritis (CAG) confirmed by upper gastrointestinal endoscopy and histopathology within the past 6 months.\n3. Ability to comprehend and voluntarily complete psychological assessments and multimodal vascular examinations.\n4. Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. History of major psychiatric disorders (e.g., schizophrenia, bipolar disorder) or currently experiencing an acute psychotic episode.\n2. Major cardiovascular or cerebrovascular events (e.g., acute myocardial infarction, stroke) within the past 3 months.\n3. Severe peripheral artery disease or major anatomical abnormalities in the lower extremities (e.g., Fontaine stage III-IV, diabetic foot with ulcers) that would preclude reliable dorsalis pedis artery ultrasound assessment.\n4. Severe hepatic or renal dysfunction, or malignancy with a limited life expectancy.\n5. Current use of systemic corticosteroids or potent immunosuppressants.\n6. Pregnancy or lactation.\n7. Any other condition deemed by the investigators to interfere with study participation or cooperation.","ALL","20 Years","60 Years",{"count":20,"type":21},520,"ESTIMATED","OBSERVATIONAL","Depressive symptoms are highly prevalent in patients with chronic atrophic gastritis (CAG) but are frequently under-detected due to stigma and reliance on subjective questionnaires. This multicenter, cross-sectional observational study aims to validate a novel clinical triage workflow. It repurposes routine vascular assessments (specifically dorsalis pedis artery ultrasound and arterial stiffness metrics) as objective \"biological entry points\" to facilitate mental health referrals. The study will enroll approximately 450-520 adults with histologically confirmed CAG across four clinical centers in China. The primary objective is to determine the diagnostic accuracy of these vascular biomarkers for identifying patients with moderate-to-severe depressive symptoms (PHQ-9 score \\>= 10). Secondary objectives include evaluating the implementation feasibility (e.g., referral uptake, screening completion rate) of this integrated care model in routine gastroenterology practice.",[25,26,27,28],"Chronic Atrophic Gastritis","Depressive Symptoms","Depression","Gastrointestinal Diseases",[30,31,32,33,34,35,36],"Vascular biomarkers","Dorsalis pedis artery ultrasound","Triage workflow","Implementation science","Stigma","Screening","Gut-brain axis","NOT_YET_RECRUITING","2025-12-21",{"date":40,"type":41},"2026-01-06","ACTUAL",{"date":43,"type":21},"2026-02-01",{"date":45,"type":21},"2026-08-30",{"name":47,"class":48},"China Academy of Chinese Medical Sciences","OTHER",4,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":5},"100604695","evaluation-of-the-efficacy-of-electroacupuncture-in-the-treatment-of-chronic-atrophic-gastritis-100604695","NCT07152860","Evaluation of the Efficacy of Electroacupuncture in the Treatment of Chronic Atrophic Gastritis","Evaluation of the Efficacy of Electroacupuncture in the Treatment of Chronic Atrophic Gastritis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Meets the diagnostic criteria for chronic atrophic gastritis (CAG) (at the time of enrolment, participants must provide reports from endoscopic and pathological examinations conducted within the past year prior to the study start date, both of which indicate chronic atrophic gastritis)\n* Age between 18 and 75 years old, no gender restrictions;\n* Has not received acupuncture treatment within the past month;\n* Not participated in any other ongoing studies within the past 2 months.\n* Understand and agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Autoimmune gastritis (type A chronic atrophic gastritis);\n* Participants with a positive C-13 urea breath test at baseline (Helicobacter pylori infection);\n* Patients diagnosed with high-grade intraepithelial neoplasia based on upper gastrointestinal endoscopy and gastric mucosal biopsy pathology;\n* Patients with confirmed or unresolved malignant tumours, particularly oesophageal cancer and gastric cancer; patients with other upper gastrointestinal lesions such as peptic ulcers or Barrett's oesophagus;\n* Patients with severe lesions in major organs (heart, liver, kidney, lung, etc.) or other autoimmune diseases (rheumatic diseases, Crohn's disease, autoimmune pancreatitis, etc.); Persons with cardiac pacemakers;\n* Pregnant and lactating women;\n* Patients with infectious diseases such as tuberculosis, hepatitis, or HIV\u002FAIDS;\n* Individuals with a history of alcohol abuse, drug use, or illicit drug use;\n* Individuals who have used other prokinetic agents, mucosal protectants, acid-suppressing medications, or related traditional Chinese medicines within the past two weeks;\n* Individuals currently participating in or who have participated in other clinical trials within the past two months; individuals unable to tolerate acupuncture or with contraindications for acupuncture treatment; and individuals deemed unsuitable for participation in this clinical trial by the research team.","18 Years","75 Years",{"count":60,"type":21},100,"INTERVENTIONAL",[63],"NA","Brief Summary Template for the Study:\n\nThis clinical trial aims to evaluate whether electroacupuncture can treat chronic atrophic gastritis (CAG) in adult subjects aged 18 to 75 years (including both males and females), all of whom have been diagnosed with CAG based on endoscopic and histopathological criteria. The primary objectives of this study are to answer the following questions:\n\n* Can 5 Hz electroacupuncture therapy reverse the pathological state of the gastric mucosa in patients with chronic atrophic gastritis?\n* Can 5 Hz electroacupuncture therapy improve gastrointestinal symptoms in patients with chronic atrophic gastritis?\n* Is there a difference in efficacy between the combination of 5 Hz electroacupuncture therapy and gastric mucosa protectants versus the use of gastric mucosa protectants alone in the treatment of chronic atrophic gastritis?\n\nResearchers will compare the effects of 5 Hz electroacupuncture combined with gastric mucosal protectants versus gastric mucosal protectants alone to determine which method can reverse the pathological state of gastric mucosa and provide more significant symptom relief.\n\nParticipants will:\n\n* Receive acupuncture treatment at specific acupoints (such as Shangwan(CV13), Zhongwan (CV12) ,Xiawan(CV10), Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39).) Electroacupuncture is administered at the abdominal points 'CV13-CV12' and 'ST21-ST21', alongside bilateral lower limb points 'ST36-ST39', using an SDZ-IIB handheld electroacupuncture device (Huatuo brand, Suzhou Medical Supplies Factory Co., Ltd.). Receive electroacupuncture treatment at 5Hz.for 30-minute sessions, three times weekly for 1-8 weeks; twice weekly from weeks 9 to 16, once weekly from weeks 17 to 24, for a total of 24 weeks, comprising 48 treatment sessions.\n* Be randomly assigned to one of the following groups: 5 Hz electroacupuncture combined with gastric mucosal protective agent group or gastric mucosal protective agent group (control group).\n* Have their dyspepsia symptoms, quality of life, and any adverse reactions continuously monitored and assessed throughout the study period.",[25],[67,68],"Chronic atrophic gastritis","electroacupuncture","2025-12-15",{"date":71,"type":41},"2025-12-19",{"date":73,"type":21},"2025-12-30",{"date":75,"type":21},"2026-12-30",{"name":77,"class":48},"Yi Liang",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":16,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100553672","objective-study-on-tongue-diagnosis-of-chronic-atrophic-gastritis-100553672","NCT06489132","Objective Study on Tongue Diagnosis of Chronic Atrophic Gastritis","Objective Study on Tongue Diagnosis of Precancerous Lesions of Chronic Atrophic Gastritis and Construction of Prediction Model","Inclusion Criteria:\n\n( 1 ) Upper gastrointestinal endoscopy was performed within 3 months ; ( 2 ) Patients with chronic atrophic gastritis diagnosed by gastroscopy and pathological examination ; ( 3 ) Age 40-70 years old, gender unlimited ; ( 4 ) agreed to collect tongue image and accept follow-up ; ( 5 ) Volunteered to participate in this study and signed informed consent.\n\nExclusion Criteria:\n\n( 1 ) those who cannot cooperate with standardized tongue image collection and data collection ; ( 2 ) patients with tongue scraping, tongue coating or abnormal tongue extension ; ( 3 ) Suspected gastric malignant tendency or gastric tumor and history of gastric surgery ; ( 4 ) Have hepatitis, syphilis, HIV, schistosomiasis and other known infectious diseases ; ( 5 ) patients with severe heart, liver, kidney, blood diseases and malignant tumors ; ( 6 ) Combined with acute respiratory tract infection, active peptic ulcer and other acute diseases ; ( 7 ) Patients who used antibiotics, acid inhibitors and microecological regulators within 1 month ; ( 8 ) long-term use of immunosuppressive agents, hormones and other drugs ; ( 9 ) pregnant or lactating women.",true,"40 Years","70 Years",{"count":89,"type":21},498,"Chronic atrophic gastritis with intestinal metaplasia or dysplasia is called precancerous lesions of gastric cancer ( PLGC ). It is an important stage in the transformation of normal mucosa to gastric cancer and is significantly associated with the risk of gastric cancer. Early identification of PLGC high-risk groups is the focus of prevention and treatment of gastric cancer. Gastroscopy and pathological examination are the key means to diagnose PLGC. However, due to the invasiveness, high cost, strong professional operability and traumatic pathological sampling, the application of gastroscopy is greatly limited, and the predictive significance of serum markers for the occurrence and prognosis of PLGC is limited. The current PLGC monitoring methods are not targeted enough, and there is still a lack of effective risk prediction models for PLGC. New screening methods are needed to improve the early diagnosis rate of PLGC. Tongue diagnosis is simple, convenient, easy and inexpensive. It can dynamically monitor the risk of PLGC in patients with chronic atrophic gastritis in early real time, and timely formulate individualized intervention measures, which is of great significance for improving the prognosis of patients, controlling medical expenses and truncating disease progression. Based on the objectification of tongue diagnosis, it may become an important method for screening PLGC from the perspective of macroscopic tongue image characteristics and microscopic tongue coating flora.",[25],[93,94,95,96,97],"Gastric precancerous lesions","tongue diagnosis","objectification","tongue coating flora","prediction model","2024-07-04",{"date":100,"type":41},"2024-07-05",{"date":102,"type":21},"2024-07",{"date":104,"type":21},"2026-03",{"name":106,"class":48},"Peking University First Hospital"]